Cancer Genetics Branch
Investigators in the Cancer Genetics Branch (CGB) seek to identify and study genes that contribute to cancer susceptibility and progression. CGB investigators are zeroing in on inherited mutations that contribute to the development of various aggressive cancers, including sarcomas and prostate, breast, and kidney cancers. They also are interested in understanding the relationship between genetic variation and cancer progression and in finding germline variants that lead, specifically, to fast-growing, aggressive tumors.
The susceptibility many types of cancers is largely inherited or results from an accumulation of genetic changes in a number of genes occurring over time. Environmental exposures also may play a significant role. To better elucidate these complex biological processes, CGB investigators are both developing new technologies and exploiting existing methods. They are particularly interested in comparative approaches and have, together with their collaborators, constructed genetic and radiation hybrid maps of the dog genome. These maps have proven invaluable in understanding the genetics of complex disease shared by humans and their pets. Such discoveries have the potential to contribute to the development of new diagnostics and therapies for improving patient survival and well-being.
Elaine A. Ostrander, Ph.D.
Chief, Cancer Genetics Branch
NIH Distinguished Investigator
Head, Comparative Genetics Section
Harold E. Varmus, M.D.
Head, Cancer Biology Section
Daphne W. Bell, Ph.D.
Head, Reproductive Cancer Genetics Section
Nigel Crawford, M.B. Ch.B., Ph.D.
Head, Metastasis Genetics Section
Settara C. Chandrasekharappa, Ph.D.
Head, Cancer Genetics Unit
James Inglese, Ph.D.
Group Leader, Assay Technology Development Group
National Center for Advancing Translational Sciences (NCATS)
Paul S. Meltzer, M.D., Ph.D.
Chief, Genetics Branch Center for Cancer Research
National Cancer Institute
Last Updated: February 10, 2014